Aldeyra Therapeutics eye treatment meets late-stage study main goal (updated)

Aldeyra Therapeutics

15/06/2023 12:26

(Adds shares in paragraph 1, details from the release in
paragraphs 2, 3)
       June 15 (Reuters) - Aldeyra Therapeutics  ALDX.O  said
on Thursday its treatment for an inflammatory eye disease met
the main goal of reducing itching in a late-stage study, sending
its shares up 16% in premarket trading.
    The liquid eye drop formulation, reproxalap, is being
developed to treat allergic conjunctivitis that leads to
swelling in a tissue lining the eyelids and white layer of the
eye.   
    The treatment also helped reduce redness and tearing caused
due to the disease when compared with placebo, the company said.
             

 (Reporting by Mariam Sunny in Bengaluru
Editing by Vinay Dwivedi)
 ((Mariam.ESunny@thomsonreuters.com;))